Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors

By sjmartinez • March 9, 2023

McDermott MSJ, O'Brien NA, Hoffstrom B, Gong K, Lu M, Zhang J, Luo T, Liang M, Jia W, Hong J, Chau K, Davenport S, Xie B, Press MF, Panayiotou R, Handly-Santana A, Brugge JS, Presta L, Glaspy J, Slamon DJ. Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors. Clin Cancer Res. 2023 Mar 8:CCR-22-2981. doi: 10.1158/1078-0432.CCR-22-2981. Epub ahead of print. PMID: 36884217.

Tags: Hematology/Oncology, Publications

Impact of Screening Mammography on Breast Cancer Outcomes in Women Aged 80 Years and Over

Huang SY, Murray M, Rubio A, Okoro N, Sedrak MS, McCloskey SA, Jackson N, Teshome M, Kapoor NS. Impact of Screening Mammography on Breast Cancer[...]

Identification of Targetable EGFR Mutations in Ovarian Cancer

Gower A, Win S, Ganguly R, Johnson M, Velez MA, Cummings AL, Lisberg A, Garon EB, Di Carlo B. Identification of Targetable EGFR Mutations in Ovarian Cancer.[...]

Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer

Chang K, Delavan HM, Yip E, Kasap C, Zhu J, Lodha R, Liao SY, Berman SC, Carretero-Gonzalez A, Basar M, Gokturk Ozcan G, Teo MY,[...]